Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 16/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25746210 | 0.81 | PDE2A (0.48) | PDE2AKMT2AHTR2C | |
| SCHEMBL30033642 | 0.80 | PDE2A (0.47) | PDE2AKMT2AHTR2CGAA | |
| SCHEMBL23579577 | 0.80 | PDE2A (0.47) | PDE2AKMT2AHTR2CGAA | |
| SCHEMBL55774 | 0.77 | PDE2A (0.64) | PDE2AKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL18343699 | 0.75 | PDE2A (0.49) | PDE2AKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL24954062 | 0.74 | PDE2A (0.47) | PDE2AKMT2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL17889388 | 0.74 | PDE2A (0.47) | PDE2AKMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL31106964 | 0.74 | PDE2A (0.47) | PDE2AKMT2AHTR2CKDM4EALDH1A1 | |
| SCHEMBL15017325 | 0.73 | PDE2A (0.45) | PDE2AKMT2A | |
| SCHEMBL27186657 | 0.73 | HTT (0.33) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-20 | — | — | US | disclosed |
| EP-4081528-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115151550-A | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-3313852-B1 | SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3313852-B1 | SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10647727-B2 | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647727-B2 | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180162874-A1 | SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162874-A1 | SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | ENPP1, ENPP3, PPA1 | PDE2A 37/4885KMT2A 4411/4885HTR2C 4192/4885 |
| US-20180162874-A1 | SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE4D | PDE2A 1/4885KMT2A 1253/4885HTR2C 106/4885 |
| US-10647727-B2 | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | PDE2A 1/4885KMT2A 1253/4885HTR2C 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.